217 related articles for article (PubMed ID: 24652560)
21. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
22. Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening.
Fachiroh J; Prasetyanti PR; Paramita DK; Prasetyawati AT; Anggrahini DW; Haryana SM; Middeldorp JM
J Clin Microbiol; 2008 Apr; 46(4):1374-80. PubMed ID: 18256216
[TBL] [Abstract][Full Text] [Related]
23. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
25. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005.
Kimura Y; Suzuki D; Tokunaga T; Takabayashi T; Yamada T; Wakisaka N; Yoshizaki T; Murata H; Miwa K; Shoujaku H; Watanabe Y; Yamada N; Ito Y; Yuta A; Takeuchi K; Hosokawa S; Mineta H; Hasegawa Y; Fujimoto Y; Nakashima T; Fujieda S
Auris Nasus Larynx; 2011 Apr; 38(2):244-9. PubMed ID: 20817430
[TBL] [Abstract][Full Text] [Related]
26. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease.
Fachiroh J; Stevens SJ; Haryana SM; Middeldorp JM
J Virol Methods; 2010 Oct; 169(1):79-86. PubMed ID: 20621126
[TBL] [Abstract][Full Text] [Related]
27. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
29. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.
Yu KJ; Hsu WL; Pfeiffer RM; Chiang CJ; Wang CP; Lou PJ; Cheng YJ; Gravitt P; Diehl SR; Goldstein AM; Chen CJ; Hildesheim A
Clin Cancer Res; 2011 Apr; 17(7):1906-14. PubMed ID: 21447725
[TBL] [Abstract][Full Text] [Related]
30. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
Clin Vaccine Immunol; 2009 May; 16(5):706-11. PubMed ID: 19321695
[TBL] [Abstract][Full Text] [Related]
31. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
32. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
Li RC; Du Y; Zeng QY; Tang LQ; Zhang H; Li Y; Liu WL; Zhong Q; Zeng MS; Huang XM
Oncotarget; 2016 Mar; 7(13):16372-83. PubMed ID: 27093005
[TBL] [Abstract][Full Text] [Related]
34. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China.
Chen H; Chen S; Lu J; Wang X; Li J; Li L; Fu J; Scheper T; Meyer W; Peng YH; Liu W
Cancer Prev Res (Phila); 2017 Sep; 10(9):542-550. PubMed ID: 28754665
[TBL] [Abstract][Full Text] [Related]
36. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
37. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
[TBL] [Abstract][Full Text] [Related]
39. Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.
Peng YH; Xu YW; Huang LS; Zhai TT; Dai LH; Qiu SQ; Yang YS; Chen WZ; Zhang LQ; Li EM; Xu LY
Cancer Prev Res (Phila); 2015 Aug; 8(8):729-36. PubMed ID: 25990085
[TBL] [Abstract][Full Text] [Related]
40. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
